Highlights

• Astec Lifesciences Limited surged around 18.99% in the latest session, reflecting a strong rebound from recent lows.
• The stock is trading near its 50-day Simple Moving Average around ₹612.42, indicating a fragile but improving short-term structure.
• Technical indicators show recovery momentum, with RSI near 54.47 supporting near-term strength.

Shares of Astec Lifesciences (NSE:ASTEC) rose nearly 18.99% to trade near ₹623.50 as of March 25, 2026, marking a sharp recovery after a sustained downtrend. The stock has now moved close to its 50-day Simple Moving Average of ₹612.42, suggesting early signs of stabilization in the price structure. However, the broader trend still reflects weakness due to earlier consistent declines.

The recent surge indicates short-term buying interest and a rebound from oversold levels, but sustained strength will depend on whether the stock can hold above key technical zones.

Financial Performance Shows Heavy Losses but Sequential Activity

Astec Lifesciences Limited reported a widened loss in Q3 FY26 despite stable revenue growth trends in parts of the business cycle. Total income stood at ₹12,551.39 lakh compared to ₹9,575.04 lakh in Q3 FY25, reflecting year-on-year growth in revenue.

However, losses remained significant. Net loss for the period stood at ₹1,571.97 lakh compared to a loss of ₹4,040.01 lakh in the same quarter last year, showing improvement on a yearly basis but still indicating weak profitability.

For the nine-month period, the company reported a loss of ₹7,322.70 lakh compared to ₹11,870.97 lakh in the previous year, indicating gradual improvement in financial performance despite continued pressure.

Revenue and Expense Trends

Revenue from operations increased to ₹12,472.03 lakh, supported by stronger sales compared to the previous year. However, high input costs continued to pressure margins.

Total expenses stood at ₹13,913.93 lakh, driven by elevated raw material costs, employee expenses, and finance costs. Finance costs alone stood at ₹717.67 lakh, reflecting ongoing leverage-related pressure.

Although certain cost categories showed stability, overall expense levels remained high, keeping the company in a loss-making position.

Technical Setup Shows Early Recovery Signs

Astec Lifesciences Limited is currently trading near ₹623.50 as of March 25, 2026, rising around 18.99%, reflecting a sharp rebound from recent lows. Despite this recovery, the price remains around its 50-day Simple Moving Average near ₹612.42, indicating a still fragile broader structure.

The chart shows a prior sequence of lower highs and lower lows, though the recent surge suggests a rebound from oversold levels with improving short-term momentum. The 14-day RSI near 54.47 supports this recovery phase. In the near term, support is placed around ₹560.00–₹530.00, while resistance is seen near ₹720.00–₹780.00.

Source: TradingView

Outlook Hinges on Recovery Continuation

In the near term, the stock’s direction will depend on whether it can sustain above the 50-day moving average and build a higher base. Continued improvement in operational efficiency and reduction in losses may support recovery attempts.

However, a sustained uptrend will require stronger earnings visibility and consistent buying interest above key resistance levels.

Risk Factors to Watch

• The company remains in a loss-making position despite improvement in scale.
  · High expense structure continues to pressure margins.
  · Broader trend is still weak with prior lower highs and lower lows.
  · Resistance near ₹720–₹780 may restrict near-term upside.

FAQs

Why did Astec Lifesciences shares rise today?

The stock gained nearly 18.99% due to strong short-term buying interest and recovery from oversold levels.

What is the key resistance level for Astec Lifesciences?

Immediate resistance is placed in the ₹720–₹780 range.

Is Astec Lifesciences profitable?

No, the company reported losses in Q3 FY26, although losses have improved year-on-year.